User‐reported outcomes of long‐acting injectable <scp>PrEP</scp> with Cabotegravir: Real‐world experience from Milan
In this real-world cohort, CAB-LA PrEP was highly acceptable, well tolerated and associated with improved perceived adherence, convenience and HIV protection. These findings support CAB-LA as a promising, user-centred HIV prevention strategy, potentially overcoming key limitations of daily oral PrEP.
Authors
- Camilla Muccini (ORCID: https://orcid.org/0000-0002-0900-5639)
- Riccardo Lolatto
- Silvia Nozza
- Gaetana Annicchiarico
- Mario Gerardo
- Angelo Roberto Raccagni (ORCID: https://orcid.org/0000-0001-7811-6255)
- Nicolò Capra (ORCID: https://orcid.org/0000-0003-1974-2015)
- Flavia Passini (ORCID: https://orcid.org/0009-0000-5492-6835)
- Caterina Candela (ORCID: https://orcid.org/0000-0001-8163-3130)
- Antonella Castagna (ORCID: https://orcid.org/0000-0001-6481-4570)
- Elena Bruzzesi (ORCID: https://orcid.org/0000-0002-3601-7686)
- Camilla Ferri
- Rossella Puzziferri
Institutions
- Vita-Salute San Raffaele University (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- HIV Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/hiv.70162
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00